Bavarian Nordic A/S announced today the award of a subcontract from Crucell Holland B.V., one of Janssen Pharmaceutical Companies of Johnson & Johnson, valued at USD 9 million. This is part of a contract awarded to Janssen by the U.S. Biomedical Advanced Research and Development Authority to support the advanced development and manufacturing of the Ebola prime-boost vaccine regimen which consists of Bavarian Nordic's MVA-BNA Filo and Ad26.ZEBOV from Janssen.